Results

Total Results: 1,185 records

Showing results for "author year description".

141. Methods Future Research Needs Number 8: Framework for Considering Study Designs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/study-design-framework_research.pdf
     March 01, 2012 - Power Calculations for Superiority RCTs for Various 5-year Primary Event Rates in the Comparator Arm … Power calculations for superiority RCTs for various 5-year primary event rates in the comparator arm11 … Plotted are power calculations for six different 5-year primary event rates in the comparator arm … Noncomparative Study Examples of this design include: A study that presents a description of a … Terms associated with study designs Term Description Cluster The term cluster refers to a unit of

142. Disposition of Comments for CER 162 Diagnosis of Celiac Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/celiac-disease_disposition-comments.pdf
     January 28, 2016 - introduction to the main body as well as the background of the executive summary should qualify the description

143. Outcomes of Serious Mental Illness | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/mental-illness-outcomes/research-protocol
     March 03, 2014 - Among adults with an SMI in 2008, less than 60 percent used any mental health services in the past year … What are potential long-term (10-year) developments in this field? Methods 1. … Specifically, our responses to GQs 1 (description and definition of QMs in SMI), 2 (context for use of … The following information will be obtained from each study, where applicable: author, year of publication … Amendments In the event of protocol amendments, the date of each amendment will be accompanied by a description

144. Disposition of Comments for Pressure Ulcer Treatment Strategies: Comparative Effectiveness (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/pressure-ulcer-treatment_disposition-comments.pdf
     May 08, 2013 - These have been added to the description. … about the exclusion of other systematic reviews which looked at comparative treatments that the author … The author is an ex-Board member of NPUAP. Summary: The rate of closure was 50% at 4-weeks. … This author also recognized that 'more recently developed pressure- relieving systems might be cost … Thus, for a clinical problem that may costs 11 billion dollars a year, we need evidence of what works

145. serious-mental-illness-outcomes-140303 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/mental-illness-outcomes_research-protocol.pdf
     March 03, 2014 - Among adults with an SMI in 2008, less than 60 percent used any mental health services in the past year … What are potential long-term (10-year) developments in this field? III. Methods 1. … Specifically, our responses to GQs 1 (description … applicable: author … Amendments In the event of protocol amendments, the date of each amendment will be accompanied by a description

146. Engaging-Caregivers-Appendix-B (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/engaging-caregivers-appendix-b.xlsx
     January 08, 2024 - Details of included studies Author, Year Study Design Country Setting/Transition Adult, Adolescent, … facility (mean stay 30 to 45 days) Adolescent Inclusion: Caregiver: 1) Legal guardian of a 12 to 17-year-old … the diary, space for text/graphical diary entries, list of terms used frequently in the ICU, and a description … Duration: 3 days Followup: 1 year NR Readmissions A vs. … test not reported) Pilot unit in hospital experienced reduction from 28.2% at baseline to 14% at 1-year

147. Disposition of Comments Report for Stroke Prevention in Atrial Fibrillation (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/stroke-atrial-fibrillation_disposition-comments.pdf
     August 23, 2013 - for non-inferiority; 1.7% per year vs. 2.2% per year for rivaroxaban and warfarin, respectively; HR … Excellent description of results. … Rates were: 0.26% per year for rivaroxaban vs. 0.44% per year for warfarin. … Rates were: 0.04% per year for rivaroxaban vs. 0.19% per year for warfarin. … Rates were: 1.53% per year for rivaroxaban vs. 1.71% per year for warfarin.

148. Disposition of Comments Report for Evidence Report/Technology Assessment No. 214 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/smoking-pregnancy-infants_disposition-comments.pdf
     February 25, 2014 - Multiple SAMHSA reports based on annual, representative household face to face surveys each year from … We contacted the author for clarification of the number of participants but did not receive a response … The evaluation covered year 1-2. … We contacted the author for clarification of the number of participants but did not receive a response … I am unaware of any inappropriate inclusions or exclusions, and, as a co-author of one of the studies

149. Multidisciplinary Postacute Rehabilitation for Moderate to Severe Traumatic Brain Injury in Adults Disposition of Comments (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/traumatic-brain-injury-rehabilitation_disposition-comments.pdf
     October 07, 2012 - Introduction On page iii of the ES, stakeholders are mentioned, but then I did not find an explicit description … Peer Reviewer #9 Methods Page ES-8, L 56: Need some description of PICOTS. … ExSumm and table 7 of the body for Key Question 2 it would be very helpful for me if you listed the Author … Added study author and year to these tables. … Peer Reviewer #5 Discussion Implications are clearly stated but there is not a sufficient description

150. Disposition of Comments for Evidence Report #208 Part 5 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/public-reporting-quality-improvement_disposition-comments.pdf
     July 26, 2012 - A detailed description is provided in Appendix F. … qualitative studies, which includes the interviews and descriptive surveys, has now been ordered by year … Author of paper, or EPC report authors? … 1) The text has been revised to clarify that this is the conclusion of the author of the paper. 2) … First author – consider having consistency of details throughout report.

151. Methods-Guidance-Reporting-Bias Methods (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-reporting-bias_methods.pdf
     November 01, 2013 - of the project or fiscal year of funding. … When trying to contact a study 19 author, there is little guidance as to how many times this … reviewers conducted by Mullan, et al.84 reported that most respondents contacted at least one study author … Trying to contact one study author three times and other study authors once is systematically different … FDA Web Site – Drugs@FDA Agency URL Description U.S.

152. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/antipsychotics-children-update-disposition-170621.pdf
     March 16, 2017 - The outcomes and description of harm types were also clear and sensible. … The most notable shortcoming was the lack of a detailed description of the meta-analytic models. … We have added this as well as more description of the methods (in Appendix G). … sub-group effects, or were removed for the various sensitivity analyses; we have added the study author … TEP 5 Discussion Good description of the limitations of the CER. What and why were explained.

153. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/antipsychotics-children-update-disposition-170621.pdf
     March 16, 2017 - The outcomes and description of harm types were also clear and sensible. … The most notable shortcoming was the lack of a detailed description of the meta-analytic models. … We have added this as well as more description of the methods (in Appendix G). … sub-group effects, or were removed for the various sensitivity analyses; we have added the study author … TEP 5 Discussion Good description of the limitations of the CER. What and why were explained.

154. Disposition of Comments Report for Primary Care Management of Abnormal Uterine Bleeding (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/abnormal-uterine-bleeding_disposition-comments.pdf
     March 21, 2013 - See Woolcock 2008; Fraser and Critchley 2007; Munro and Critchley 2011 A description of terminology … Peer Reviewer #7 (TEP) Introduction p. 4 l.13-14 l. 23 This is too simplistic a description of … Line 23 “encourage endometrial quiescence” and “prevent growth” are the type of description I would … Results p. 26 l. 25 There is a RCT from Scandanavia comparing LNG-IUS with hysterectomy with 5+ year … This may not have been captured, but it is RCT with followup beyond a year.

155. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ptsd-5-protocol-update-2023.pdf
     January 01, 2023 - After studies are screened and determined to meet inclusion criteria, we will abstract study design, year … Data Synthesis: Characteristics of included studies, such as number of publications by year, study sample … Author 2. Year of publication 3. Bibliographic citation 4. PubMed ID 5. … Year of publication 2. Study class 3. Country/Countries of study sites 4. Site type 5. … Treatment Description 4.

156. Cer-235-Pharma-Nonpharm-Ptsd-Update-Appendix-G-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-235-pharma-nonpharm-ptsd-update-appendix-g-1.xlsx
     November 12, 2020 - Additions to risk of bias template Rater Author, Year Selection Bias Domain: Randomization Adequate? … Center ROB Risk of bias RTI-UNC RTI-UNC Evidence-based Practice Center NOTE: Each column includes a description

157. Cer-235-Pharma-Nonpharm-Ptsd-Update-Appendix-G-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-235-pharma-nonpharm-ptsd-update-appendix-g-1.xlsx
     November 12, 2020 - Additions to risk of bias template Rater Author, Year Selection Bias Domain: Randomization Adequate? … Center ROB Risk of bias RTI-UNC RTI-UNC Evidence-based Practice Center NOTE: Each column includes a description

158. Renal Artery Stenosis Update | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/renal-update/research-protocol
     January 20, 2015 - effectiveness reviews, and will include elements that address population characteristics including description … between the comparative groups or overall high loss to follow-up, and the validity and adequacy of the description … descriptions of the study design, intervention(s), mean baseline blood pressure and kidney function, description

159. Effectiveness of Screening and Treatment of Subclinical Hypothyroidism or Hyperthyroidism (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/hypothyroidism-hyperthyroidism-screening-treatment_disposition-comments.pdf
     February 01, 2012 - We added a description of myxedema coma Source: http://www.effectivehealthcare.ahrq.gov/index.cfm … UPdate...nearly 1 year old). … Introduction p. 14, line 43--on the third review, state number and type of studies We have added this description … As noted above, these two studies are problematic and there is no evidence to support a 1-2 year observation … We removed the “1-2 year” from the sentence Peer Reviewer #6 Results Table 10AB is great, except

160. Technical Brief Disposition of Comments Report for Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/colon-cancer-gene-profiling_disposition-comments.pdf
     December 14, 2012 - Public Seidenfeld Background P 1 Relative 5-year survival rate Since estimates for stage I and across … However, in the description of studies excluded from the literature review on page 11 the authors state … (Beginning) There is a description of the GEPs. … The 5-year distant-metastasis free survival was 95% for low risk patients and 80% for high risk patients … The 3-year RFS was 91% for Low Risk and 74% for High Risk patients with a HR of 2.9 (p=0.001).”